Not all photographs in this mailing are of actual patients. Jakafi is not indicated for children.

Starting Your Treatment With Jakafi®

Welcome to IncyteCARES, your connection to benefits and ongoing support during your treatment with Jakafi for intermediate or high-risk myelofibrosis.

By now, you should have had a chance to speak with a professional from IncyteCARES about
- How to take Jakafi properly
- What to expect from treatment with Jakafi
- Features of the IncyteCARES program
- A brief overview of the Patient Packet you received along with your Jakafi

As an IncyteCARES professional may have explained, your Jakafi will be mailed to your home from a specialty pharmacy. In the future, you will continue to receive phone calls from the pharmacy when it’s time for a refill or if you miss your refill.

If you have any questions about your prescription for Jakafi, please call your doctor, or an IncyteCARES representative at 1-855-4-Jakafi (855-452-5234). If you need help paying for Jakafi, please contact an IncyteCARES representative at 1-855-4-Jakafi (855-452-5234) to see if you are eligible for financial assistance.

Information in this booklet is not intended to replace the advice of your doctor. Please see Important Safety Information on pages 14 and 15 and accompanying Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.
Jakafi® (ruxolitinib)

Why Have I Been Prescribed Jakafi® (ruxolitinib)?

Your doctor has prescribed Jakafi because you have intermediate or high-risk myelofibrosis. Your doctor may have explained to you that myelofibrosis can cause a build-up of scar tissue in your bone marrow. When this happens:

- Your bone marrow is not able to make enough blood cells or blood cells are released too quickly from the bone marrow and don’t have time to fully form.
- When the bone marrow can’t make enough blood cells, the spleen takes over and begins to make blood cells.
- This production or storage of blood cells causes the spleen to enlarge.

An enlarged spleen can cause some of the symptoms you may have, such as:

- Abdominal discomfort
- Early feeling of fullness
- Pain under the left ribs

Myelofibrosis can also cause other symptoms not related to the spleen. Some examples include:

- Itching
- Night sweats
- Bone/muscle pain

During treatment with Jakafi, you may notice an improvement in these symptoms, and your doctor may tell you that your spleen has become smaller. Your doctor may discontinue your therapy after 6 months on treatment if you and your doctor believe you are not benefiting from therapy.

Understanding Your Prescription

With each bottle of Jakafi that you receive, you will find a document called the “Prescribing Information” (PI). The PI contains facts you should know about Jakafi, including:

- What it is approved to treat
- How it works
- How to take it
- What side effects it may cause
- What interactions it may have with other medicines or drinks/foods

The PI is a helpful place to look for answers to these and other questions you may have about Jakafi.

Included in the back of the PI is Patient Information, also sometimes called the “Patient Package Insert,” or PPI. The PPI contains information about Jakafi in simple, straightforward language.

It is important that you read this document each time you get a refill of Jakafi because there may be new information.

This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

Important Safety Information to Consider

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.

These are not all the possible side effects of Jakafi.

Talk to your healthcare provider or pharmacist about any questions or concerns you may have.

Please see pages 14 and 15 to learn more about these and other side effects of Jakafi.

Jakafi is a prescription medicine used to treat people with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. If you are unclear about what type of myelofibrosis you have and what it means, be sure to ask your doctor.
How Does Jakafi® (ruxolitinib) Work?

To understand how Jakafi treats the symptoms of intermediate or high-risk myelofibrosis, it helps to know a little bit about what might cause the disease. Although scientists do not know the exact cause of myelofibrosis, they believe that one cause is “overactive JAK signaling.” What does this mean?

- The body makes proteins called JAKs (Janus kinases)
- JAKs send signals from one cell to another
- These signals help the body make the right number of blood cells and certain proteins called cytokines (SUY-te-kynes)
- In a person with myelofibrosis, JAKs send too many signals
- As a result, the body makes the wrong number of blood cells and too many cytokines

How does JAK signaling become overactive? In some people, mutations called JAK2V617F or JAK2 mutations may be responsible. But even people with myelofibrosis who do not have these mutations are believed to have overactive JAK signaling for other reasons.

Jakafi has been shown to decrease overactive JAK signaling, thought to be a major cause of myelofibrosis. Jakafi may also decrease the amount of cytokines in your body. Cytokines can cause the itching and night sweats you may have.

Jakafi may cause certain blood counts to become lower, such as hemoglobin, white blood cells, and platelets. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your doctor will regularly check your blood counts to evaluate any blood-related side effects. Let your doctor know right away if you experience any unusual bleeding, bruising, fatigue, shortness of breath, or fever.

Important Safety Information to Consider

Jakafi can cause serious side effects, including:

- Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters. These are not all the possible side effects of Jakafi.

Please see pages 14 and 15 to learn more about these and other side effects of Jakafi.
Important Safety Information to Consider

Jakafi can cause serious side effects, including:

- **Low blood counts**: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.

- **Infection**: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters. These are not all the possible side effects of Jakafi. Talk to your healthcare provider or pharmacist about any questions or concerns you may have. Please see pages 14 and 15 to learn more about these and other side effects of Jakafi.

---

**Setting Expectations: Understanding Your Treatment With Jakafi® (ruxolitinib)**

You may have already received a Patient Packet of materials introducing you to the IncyteCARES program and treatment with Jakafi. If you did not receive this packet, you can call 1-855-4-Jakafi (855-452-5234) and ask an IncyteCARES representative to send you one.

You are encouraged to read this brochure and talk to your doctor about any questions you may have. Here are key highlights of the information you will find.

- **Jakafi may achieve 2 important goals of treatment:**
  - Reduce the size of the spleen
  - Improve core symptoms, such as abdominal discomfort, pain under the left ribs, an early feeling of fullness, itchiness, bone or muscle pain, and night sweats

- **During your treatment with Jakafi, your doctor will likely perform regular complete blood counts (CBCs)**

- **Based on the results of your CBCs, your doctor may adjust your dose of Jakafi or interrupt your treatment**

One of the resources included in the Patient Packet is a brochure titled *What to Expect When Taking Jakafi*. This brochure describes the possible benefits and side effects of Jakafi. It also guides you through what you will experience in working with your doctor as you start and continue treatment with Jakafi.

It is important to remember that each person is different. How one person responds to Jakafi may not be the same as the way another person responds. Speak with your doctor about how your treatment with Jakafi can be managed.

- **Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. These side effects can be serious. If you develop bleeding, stop taking Jakafi and call your healthcare provider. See the Important Safety Information to learn more about this and other possible risks**

- **Anemia is a common consequence of myelofibrosis, and people can develop anemia while taking Jakafi. Anemia may require treatment including changing your dose of Jakafi or a blood transfusion. Doctors are used to managing anemia, and you may still be able to continue taking Jakafi for your condition.**

**Possible Benefits of Jakafi**

- **Spleen-related symptoms**
  - Early feeling of fullness
  - Abdominal discomfort
  - Night sweats
  - Bone/muscle pain
  - Itching

**Possible Side Effects of Jakafi**

- **Low blood counts:** Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. These side effects can be serious. If you develop bleeding, stop taking Jakafi and call your healthcare provider. See the Important Safety Information to learn more about this and other possible risks.

- **Anemia**
  - Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. These side effects can be serious. If you develop bleeding, stop taking Jakafi and call your healthcare provider. See the Important Safety Information to learn more about this and other possible risks.

- **Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. These side effects can be serious. If you develop bleeding, stop taking Jakafi and call your healthcare provider. See the Important Safety Information to learn more about this and other possible risks.**

It is important to remember that drops in hemoglobin levels caused by Jakafi can occur when the spleen becomes enlarged. It is important to remember that an enlarged spleen can worsen over time. While every person is different, your doctor may want to keep you on Jakafi for up to 6 months to see if your symptoms improve.

**Information in this booklet is not intended to replace the advice of your doctor.**
Jakafi can cause serious side effects, including:

- Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.

- Infection: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.

These are not all the possible side effects of Jakafi. Talk to your healthcare provider or pharmacist about any questions or concerns you may have.

IncyteCARES Can Help You Get Access to Jakafi

In addition to providing you with education about myelofibrosis and treatment with Jakafi, the IncyteCARES program offers Access and Reimbursement Services to patients who are taking Jakafi and who qualify for this program. You may already have taken advantage of this assistance, and you can continue to do so if you have any questions or any changes in your treatment. Feel free to reach out to IncyteCARES if

- Your doctor has changed your dose of Jakafi and you have questions or concerns
- Your insurance has changed
- You are having any challenges paying for Jakafi

Remember, IncyteCARES professionals are available to help you understand your healthcare benefits, get help with insurance coverage for Jakafi, and coordinate delivery of Jakafi from your specialty pharmacy. They can provide access to financial assistance in affording some costs associated with your prescription for Jakafi, such as free drug if you do not have insurance, or co-payment assistance. They can refer you to independent, nonprofit organizations that can find ways to help you with your co-payment.

For more information about IncyteCARES services, review the brochure found in your Patient Packet or visit www.jakafi.com/incytecares.

Communicating With Your Pharmacies: A Key to Treatment With Jakafi® (ruxolitinib)

As you know, your Jakafi arrives to your door each month from a specialty pharmacy. A specialty pharmacy provides home delivery of certain medicines that treat complex conditions, like myelofibrosis. These drugs may require special handling and other specialty expertise.

Many specialty pharmacies also offer other services that you may find helpful, including:

- Detailed personal instruction on how to take your medicine
- Around-the-clock support (by phone)
- Proactive refills through automatic refill services
- Coordination with your doctor and other caregivers to ensure that you have the medicines and supplies you need for your care
- Free educational materials
- Coordination of home health care services, if needed

Coordination with your care team—including your local pharmacy—is particularly important. It is critical that you:

- Tell your local pharmacy that you are taking Jakafi and that you get it from a specialty pharmacy
- Tell your specialty pharmacy about all other medicines you are taking, including over-the-counter treatments

This will help to reduce the chance of interactions between Jakafi and any other medicines you are taking.

IncyteCARES Can Help You Get Access to Jakafi

In addition to providing you with education about myelofibrosis and treatment with Jakafi, the IncyteCARES program offers Access and Reimbursement Services to patients who are taking Jakafi and who qualify for this program. You may already have taken advantage of this assistance, and you can continue to do so if you have any questions or any changes in your treatment. Feel free to reach out to IncyteCARES if

- Your doctor has changed your dose of Jakafi and you have questions or concerns
- Your insurance has changed
- You are having any challenges paying for Jakafi

Remember, IncyteCARES professionals are available to help you understand your healthcare benefits, get help with insurance coverage for Jakafi, and coordinate delivery of Jakafi from your specialty pharmacy. They can provide access to financial assistance in affording some costs associated with your prescription for Jakafi, such as free drug if you do not have insurance, or co-payment assistance. They can refer you to independent, nonprofit organizations that can find ways to help you with your co-payment.

For more information about IncyteCARES services, review the brochure found in your Patient Packet or visit www.jakafi.com/incytecares.

Important Safety Information to Consider

Jakafi can cause serious side effects, including:

- Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.

- Infection: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.

These are not all the possible side effects of Jakafi. Talk to your healthcare provider or pharmacist about any questions or concerns you may have.

Please see pages 14 and 15 to learn more about these and other side effects of Jakafi.
Resources and Support

A number of nonprofit organizations have Web sites that offer information and resources about myelofibrosis. Incyte Corporation is not affiliated with these organizations but has provided funding for some of their educational programs.

**CancerCare**
Phone: 1-888-813-HOPE (4673)  www.cancercare.org
CancerCare provides free support services for people affected by cancer, including resources about coping with cancer, managing side effects of treatment, and financial support, as well as facts about myelofibrosis. CancerCare also provides access to professional counseling, support groups, and community groups.

**Cancer Support Community (CSC)**
Phone: 1-202-859-9709  www.cancersupportcommunity.org
CSC offers educational services, such as a booklet of medication information about myelofibrosis, and resources for patients and caregivers. Emotional support through online and local support groups, counseling, and family/caregiver workshops are provided, as well as information on how to gain financial assistance.

**Leukemia & Lymphoma Society (LLS)**
Phone: 1-800-955-4572  www.lls.org
Free services offered by LLS include an information resource center, clinical trial information, national and local education programs, support groups, an online patient forum, and financial assistance. These services are provided with the goal of improving the quality of life for patients and their families.

**MPN Education Foundation**
www.mpninfo.org
The MPN Education Foundation offers materials and resources dedicated specifically to myelofibrosis and myeloproliferative neoplasms (MPNs), including videos and medical information. A free online support group for patients with MPNs, called MPN-NET, provides access to online discussions about patient experiences, psychosocial issues, and information and reassurance for patients and caregivers.

**MPN Research Foundation**
Phone: 1-312-683-7249  www.mpnresearchfoundation.org
MPN Research Foundation specializes in education and support services for people living with myelofibrosis and other MPNs. The Foundation offers 30 live support groups throughout the country, both in person and online.

**National Association for Rare Disorders (NORD)**
Phone: 1-203-744-0100  www.rarediseases.org
NORD serves as a federation of voluntary health organizations and individuals dedicated to helping people with “orphan” diseases get access to educational resources, emotional support, and online communities.

**Patient Advocate Foundation (PAF)**
Phone: 1-800-532-5274  www.patientadvocate.org
PAF works to safeguard patients by assuring access to care, maintenance of employment, and preservation of financial stability. Services include online educational materials, a patient hotline, financial aid, and Spanish services.

**The MPN Coalition**
The MPN Coalition is a group of organizations that came together to provide a forum for discussion of, and action on, needs and challenges faced by those living with and affected by MPNs, including myelofibrosis. The Coalition aims to create greater awareness of these rare diseases and to enhance education and access to care.

The organizations that make up the MPN Coalition are:
- CancerCare
- Cancer Support Community
- Leukemia & Lymphoma Society
- MPN Education Foundation
- MPN Research Foundation
- National Association for Rare Disorders

**CancerCare**
Phone: 1-888-813-HOPE (4673)  www.cancercare.org
CancerCare provides free support services for people affected by cancer, including resources about coping with cancer, managing side effects of treatment, and financial support, as well as facts about myelofibrosis. CancerCare also provides access to professional counseling, support groups, and community groups.

**Cancer Support Community (CSC)**
Phone: 1-202-859-9709  www.cancersupportcommunity.org
CSC offers educational services, such as a booklet of medication information about myelofibrosis, and resources for patients and caregivers. Emotional support through online and local support groups, counseling, and family/caregiver workshops are provided, as well as information on how to gain financial assistance.

**Leukemia & Lymphoma Society (LLS)**
Phone: 1-800-955-4572  www.lls.org
Free services offered by LLS include an information resource center, clinical trial information, national and local education programs, support groups, an online patient forum, and financial assistance. These services are provided with the goal of improving the quality of life for patients and their families.

**MPN Education Foundation**
www.mpninfo.org
The MPN Education Foundation offers materials and resources dedicated specifically to myelofibrosis and myeloproliferative neoplasms (MPNs), including videos and medical information. A free online support group for patients with MPNs, called MPN-NET, provides access to online discussions about patient experiences, psychosocial issues, and information and reassurance for patients and caregivers.

**MPN Research Foundation**
Phone: 1-312-683-7249  www.mpnresearchfoundation.org
MPN Research Foundation specializes in education and support services for people living with myelofibrosis and other MPNs. The Foundation offers 30 live support groups throughout the country, both in person and online.

**National Association for Rare Disorders (NORD)**
Phone: 1-203-744-0100  www.rarediseases.org
NORD serves as a federation of voluntary health organizations and individuals dedicated to helping people with “orphan” diseases get access to educational resources, emotional support, and online communities.

**Patient Advocate Foundation (PAF)**
Phone: 1-800-532-5274  www.patientadvocate.org
PAF works to safeguard patients by assuring access to care, maintenance of employment, and preservation of financial stability. Services include online educational materials, a patient hotline, financial aid, and Spanish services.

**The MPN Coalition**
The MPN Coalition is a group of organizations that came together to provide a forum for discussion of, and action on, needs and challenges faced by those living with and affected by MPNs, including myelofibrosis. The Coalition aims to create greater awareness of these rare diseases and to enhance education and access to care.

The organizations that make up the MPN Coalition are:
- CancerCare
- Cancer Support Community
- Leukemia & Lymphoma Society
- MPN Education Foundation
- MPN Research Foundation
- National Association for Rare Disorders

Jakafi can cause serious side effects, including:

**Low blood counts:** Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.

**Infection:** You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.

**These are not all the possible side effects of Jakafi.**
Talk to your healthcare provider or pharmacist about any questions or concerns you may have.

Please see pages 14 and 15 to learn more about these and other side effects of Jakafi.
Important Safety Information to Consider

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.

These are not all the possible side effects of Jakafi.

Talk to your healthcare provider or pharmacist about any questions or concerns you may have.

Please see pages 14 and 15 to learn more about these and other side effects of Jakafi.

Social Network Resources

Learn more about living with myelofibrosis through these social network sites:

- [www.mpnforum.com](http://www.mpnforum.com)
- [www.jakafi.com/facebook](http://www.jakafi.com/facebook)

A number of nonprofit organizations offer education and resources that can help you better understand what to expect as your loved one’s myelofibrosis progresses. Here are just a few:

- [www.lls.org/#/diseaseinformation/myeloproliferativediseases/idiopathicmyelofibrosis](http://www.lls.org/#/diseaseinformation/myeloproliferativediseases/idiopathicmyelofibrosis)
- [www.rarediseases.org/rare-disease-information/rare-diseases/](http://www.rarediseases.org/rare-disease-information/rare-diseases/)
- [www.mpninfo.org/faq/faq mf.html](http://www.mpninfo.org/faq/faq mf.html)
- [www.mpnresearchfoundation.org/Primary-Myelofibrosis](http://www.mpnresearchfoundation.org/Primary-Myelofibrosis)

A Message for Caregivers

Every person with myelofibrosis is different, and what your loved one may experience may be different from another person. Participating in discussions with your loved one and the doctor or, if your loved one allows, talking directly with the doctor, are the best ways to get answers to questions about what you can expect.

If you have any questions about what your loved one is going through or what you can expect from continued treatment with Jakafi® (ruxolitinib), reach out to an IncyteCARES specialist at 1-855-4-Jakafi (855-452-5234). He or she can help you better understand:

- What side effects may occur
- Why and when the dose of Jakafi may be changed

In the Patient Packet is an informational brochure written just for you—the caregiver. You will find answers to many of your questions about myelofibrosis and treatment with Jakafi. If you have not received this brochure, please contact IncyteCARES.
Jakafi can cause serious side effects, including:

**Low blood counts:** Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.

**Infection:** You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.

The most common side effects of Jakafi include dizziness and headache.

These are not all the possible side effects of Jakafi. Ask your healthcare provider or pharmacist for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or have had liver or kidney problems, are on dialysis, or have any other medical condition. Do not drink grapefruit juice while taking Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see accompanying Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.
Not all photographs in this mailing are of actual patients.

Jakafi is not indicated for children.

Starting Your Treatment With Jakafi®

Welcome to IncyteCARES, your connection to benefits and ongoing support during your treatment with Jakafi for intermediate or high-risk myelofibrosis.

By now, you should have had a chance to speak with a professional from IncyteCARES about

- How to take Jakafi properly
- What to expect from treatment with Jakafi
- Features of the IncyteCARES program
- A brief overview of the Patient Packet you received along with your Jakafi

As an IncyteCARES professional may have explained, your Jakafi will be mailed to your home from a specialty pharmacy. In the future, you will continue to receive phone calls from the pharmacy when it’s time for a refill or if you miss your refill. If you have any questions about your prescription for Jakafi, please call your doctor, or an IncyteCARES representative at 1-855-4-Jakafi (855-452-5234).

If you need help paying for Jakafi, please contact an IncyteCARES representative at 1-855-4-Jakafi (855-452-5234) to see if you are eligible for financial assistance.

Information in this booklet is not intended to replace the advice of your doctor. Please see Important Safety Information on pages 14 and 15 and accompanying Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.